KLK3 and prostate carcinoma: In 2017, a study suggested that combining GVAX with cyclophosphamide and degarelix as neoadjuvant therapy for high-risk prostate cancer could potentially enhance outcomes concerning time-to-prostate-specific antigen (PSA) relapse [114].